Target Degradability Assessment for TPD Development
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Not every protein is a good degradation target. Targeted protein degradation (TPD) only works when the target protein can be successfully recruited by a degrader, form a productive complex with a suitable E3 ligase, present accessible lysine residues for ubiquitin transfer, and ultimately be processed by the proteasome or another degradation pathway. BOC Sciences provides comprehensive target degradability assessment services that answer the single most important question before any chemistry resources are committed: can this target actually be degraded, and if so, how? Our assessment combines ligand binding and structural characterization, cellular target engagement, E3 ligase compatibility evaluation, ternary complex and ubiquitination analysis, degradation efficiency and kinetics quantification, pathway validation, and proteome-wide selectivity profiling, giving pharmaceutical and biotechnology researchers a data-driven basis for target selection, degradation strategy design, and project go/no-go decisions.
Request a Consultation Explore ServicesServices
BOC Sciences Target Degradability Assessment Services
Our services are organized as a panel of orthogonal assay modules that together cover every mechanistic step of the degradation process. Clients can commission a single assay module to answer a specific question, or combine multiple modules into an integrated degradability assessment program tailored to their target class and project stage.
Ligand Binding and Structural Characterization Assays
Degradation starts with binding. We first confirm that the target protein possesses a ligandable pocket and map exactly how a ligand occupies it, using binding affinity measurement platforms such as SPR, ITC, and MST, structural biology approaches including co-crystallization and cryo-EM, plus HDX-MS for conformational dynamics.
Assay Platform What It Measures Key Readouts Surface plasmon resonance (SPR) Purified target protein immobilized on a chip, ligand flowed across the surface Kd, association rate (kon), dissociation rate (koff) Isothermal titration calorimetry (ITC) Heat changes during ligand titration into target protein solution Kd, binding stoichiometry, enthalpy change (ΔH) Microscale thermophoresis (MST) Thermophoretic shifts induced by ligand binding to a labeled target Kd, binding specificity confirmation X-ray co-crystallography Atomic structure of the ligand-protein complex Pocket geometry, key interacting residues, linker exit vectors Cryo-EM Structures of large complexes or proteins resistant to crystallization 3D structure, allosteric and protein-protein interface sites HDX-MS Deuterium exchange kinetics reflecting ligand-induced conformational shifts Binding-induced conformational changes, cryptic pocket exposure 
Cellular Target Engagement Assays
Biochemical binding does not guarantee that a ligand reaches and engages the target inside intact cells. Our cellular engagement assays, integrated within broader PROTAC in vitro evaluation workflows, verify intracellular binding under physiological conditions.
Assay Platform What It Measures Key Readouts BRET-Based cellular target engagement assay Bioluminescence resonance energy transfer between ligand and tagged target in live cells Intracellular Kd, binding site confirmation Thermal shift assays Ligand-induced stabilization of the target protein in cellular lysates or intact cells Cellular thermal shift, direct engagement evidence Cellular pull-down Recovery of target protein by an immobilized ligand probe from living cells Occupancy, permeability-dependent engagement Split-Luciferase Complementation Assay Reporter-based quantification of ligand occupancy at the endogenous target Engagement potency, residence time trends 
E3 Ligase Compatibility Assessment Assays
A target can only be degraded in cells where a suitable, active E3 ligase is expressed and co-localized with the target. We profile E3 ligase expression and functional activity across disease-relevant models, supported by quantitative E3 ubiquitin ligase activity assays.
Assay Platform What It Measures Key Readouts RNA-seq / single-cell sequencing mRNA levels of E3 ligases across cell types and disease models Tissue and cell-type-specific E3 expression landscape Targeted proteomics (PRM / HRM) Absolute quantification of E3 ligase protein abundance E3 protein levels, disease versus normal comparison Immunohistochemistry (IHC) Spatial distribution of E3 ligases in tissue sections Subcellular localization, heterogeneity of expression In vitro ubiquitination assays Catalytic competence of the E3 ligase toward substrate ubiquitination Functional activity state, impact of mutations E3 knockout / knockdown (CRISPR, siRNA) Loss of E3 function on observed degradation E3 dependency confirmation 
Ternary Complex Formation and Cooperativity Assays
For bifunctional degraders, degradation efficiency is governed by the stability and geometry of the target-degrader-E3 ternary complex, not merely by binary affinity. Our PROTAC ternary complex assay portfolio measures ternary complex formation, cooperativity, and intracellular proximity.
Assay Platform What It Measures Key Readouts TR-FRET / Bead-Based Luminescent Proximity Assay Reconstituted ternary complex formation with purified proteins in vitro Ternary complex affinity, cooperativity factor (α) Cellular BRET-Based ternary complex assay Target-E3 proximity in live cells mediated by the degrader Intracellular ternary formation, hook effect characterization Co-immunoprecipitation (Co-IP) Physical association between target and E3 ligase in cell lysates Cellular ternary complex detection Proximity ligation assay Endogenous protein pairs within 40 nm visualized in situ Single-cell ternary complex imaging, subcellular co-localization BioID / TurboID proximity labeling Proximity-dependent labeling followed by MS identification Proteome-scale interaction maps, neo-substrate discovery 
Target Ubiquitination Assays
Ubiquitin transfer onto accessible lysine residues is the decisive biochemical step of UPS-mediated degradation. Our protein ubiquitination services and the TR-FRET in vitro ubiquitylation assay reveal whether the target can actually be ubiquitinated in the right place and with the right chain topology.
Assay Platform What It Measures Key Readouts IP-western ubiquitin detection Immunoprecipitated target probed for ubiquitin signal Polyubiquitination smear intensity, time dependence Ubiquitin chain topology analysis Linkage types decorating the target protein K48 / K63 chain profiles, proteasome-directed signal confirmation MS-based ubiquitination site mapping Exact lysine residues modified by ubiquitin Ubiquitination site inventory, accessibility interpretation TR-FRET / ELISA ubiquitylation assays Substrate ubiquitination kinetics in a reconstituted system Ubiquitination rate, E3/E2 dependence 
Target Degradation Efficiency and Kinetics Assays
The clearest degradability readout is the depth and speed of target loss in cells. We quantify degradation using our degradation ability assay modules, which measure DC50, Dmax, degradation rate, and protein resynthesis dynamics in disease-relevant cellular models.
Assay Platform What It Measures Key Readouts Western blot / capillary immunoassay Residual target protein levels after degrader treatment DC50, Dmax, exposure-response curves In-Cell Western High-throughput quantitative target detection in plate format High-throughput DC50 screening, analog ranking Cycloheximide chase Remaining target protein over time after synthesis blockade Protein half-life (t1/2), degradation rate constant Flow cytometry Surface or intracellular target levels at single-cell resolution Degradation efficiency, cell-to-cell heterogeneity Immunofluorescence / confocal imaging Subcellular localization and clearance of the target Visualization of degradation, compartment-specific effects Degradation Pathway Validation Assays
Demonstrating why the target disappears is as important as demonstrating that it disappears. We use mechanism-of-action tools established in ubiquitin-proteasome based degradation technology development to confirm that protein loss proceeds through the intended UPS route, or alternatively through lysosomal pathways for extracellular and membrane targets.
Assay Platform What It Measures Key Readouts Proteasome inhibition (MG132, bortezomib, carfilzomib) Rescue of target levels upon proteasome blockade UPS dependence confirmation Neddylation inhibition (MLN4924) Contribution of cullin-RING ligase complexes CRL-type E3 involvement Lysosomal inhibition (chloroquine, bafilomycin A1, NH4Cl) Rescue of target levels upon lysosome blockade Lysosomal pathway dependence (LYTAC, AUTOTAC-type routes) E3 ligase knockout / knockdown Effect of removing the designated E3 ligase E3 dependency of the observed degradation Autophagy marker monitoring LC3-II conversion and p62/SQSTM1 recruitment Autophagy-lysosome route confirmation Proteomics-Based Degradation Selectivity Assays
A credible degradability conclusion requires evidence that observed protein loss is selective rather than broadly toxic. Our PROTAC selectivity evaluation and off-target evaluation capabilities profile the whole proteome to separate genuine target degradation from unintended protein loss.
Assay Platform What It Measures Key Readouts Global proteomics (LC-MS/MS, TMT or label-free) Abundance changes across thousands of proteins after treatment Selectivity index, off-target protein identification Thermal proteome profiling (TPP / CESTA) Ligand-induced melting temperature shifts proteome-wide Direct engagement confirmation in intact cells LiP-MS Proteolytic sensitivity changes upon ligand binding Binding-induced conformational changes, cryptic pocket detection Phosphoproteomics Downstream signaling changes after target degradation Pathway suppression verification, off-pathway activity exclusion
Is Your Target Protein a Good Degradation Candidate?
From pocket analysis to cellular degradation kinetics, we help you understand whether your target can be degraded before you invest in degrader synthesis.
Target Classes
Protein Classes for Target Degradability Assessment
Enzymes with deep active-site pockets are historically the most straightforward targets, whereas transcription factors, membrane proteins, and secreted proteins each impose distinct structural and pathway constraints. BOC Sciences tailors every degradability assessment to the biology of the target class involved.
Kinases and Other Enzymes
Enzymes remain the most degrader-friendly class because catalytic and allosteric pockets provide clear starting points for ligand discovery, and loss of enzymatic activity gives a direct functional readout. Representative targets include BTK, CDK4/6, EGFR, and BCR-ABL, where our assessment asks whether degradation adds value over inhibition by eliminating scaffolding functions that persist in inhibited enzymes. Learn more about our experience with PROTACs targeting protein kinases.
- Active-site and allosteric pocket characterization
- Catalytic versus scaffold function comparison after degradation
- Known ligand chemotype repositioning for degrader design
Transcription Factors and Nuclear Receptors
Transcription factors drive many disease programs yet often lack classical druggable pockets, making ligandability the central degradability question; representative examples include STAT3, MYC, and IRF4. Nuclear receptors such as ERα and AR are more tractable thanks to their ligand-binding domains, and our work on PROTACs targeting nuclear receptors illustrates how pocket availability shapes degradation outcomes. For pocketless factors, we evaluate molecular glue technology routes and intrinsically disordered region contributions to proteasomal processing.
- DNA-binding domain and ligand-binding domain ligandability analysis
- Downstream gene expression network verification
- IDR proportion and proteasomal accessibility estimation
Scaffolding and Adaptor Proteins
Scaffolding and adaptor proteins assemble signaling complexes without performing catalysis, so traditional inhibitors often fail to disrupt their biological roles. Representative disease-relevant scaffolds include IRAK4, RIPK1, and β-catenin, where protein degradation removes the entire protein together with all of its interaction surfaces, making this class a natural TPD advantage area where our assessment focuses on whether the relevant protein-protein interaction interfaces remain accessible in the assembled complex.
- PPI interface mapping within native complexes
- Complex immunoprecipitation and stability analysis
- Functional rescue design distinguishing loss of scaffold from loss of signal
Epigenetic and Chromatin-Associated Proteins
Epigenetic readers, writers, and erasers frequently contain well-defined binding modules such as bromodomains, making them highly ligandable degrader targets. A validated example from our practice is the PROTAC targeting BRD4, and we extend the same logic to other regulators such as EZH2 and HDAC6 across chromatin-associated complexes that lack classical pockets.
- Reader, writer, and eraser module pocket analysis
- Chromatin complex context and co-localization assessment
- Selectivity profiling across homologous family members
Membrane Receptors and Transporters
Membrane proteins sit in a lipid environment that standard UPS recruiting cannot easily reach. Targets such as HER2, EGFR, and PD-L1 illustrate why our assessment distinguishes two routes: classic PROTAC designs engaging intracellular segments with accessible pockets, and lysosome-directed strategies such as LYTAC- and AbTAC-type approaches that harness receptor internalization. Explore our dedicated membrane protein degradation capabilities for this class.
- Surface expression and internalization rate quantification
- Intracellular segment pocket evaluation
- Lysosomal delivery efficiency characterization
Extracellular and Secreted Proteins
Secreted and extracellular proteins fall outside the reach of intracellular E3 ligases, so their degradability depends entirely on whether they can be routed into lysosomal degradation, for example through receptor-mediated uptake. Representative evaluation targets in this class include disease-associated cytokines, growth factors, and circulating enzymes. Our assessment therefore evaluates extracellular target abundance, available uptake receptors, and lysosomal shuttling capacity, building on our extracellular protein degradation technology experience.
- Uptake receptor and shuttling pathway identification
- Extracellular abundance and turnover measurement
- Lysosomal routing strategy comparison
Importance
Why Target Degradability Assessment Matters for TPD Programs?
Identify Feasible Targets for Protein Degradation
TPD portfolios fail more often from target choice than from degrader chemistry. A structured degradability assessment tells you upfront which programs are worth pursuing, so resources concentrate on targets that can realistically be degraded.
Reveal Barriers to Effective Target Degradation
When degradation underperforms, the cause is rarely obvious. Our orthogonal assay logic pinpoints whether the bottleneck lies in ligandability, E3 compatibility, ternary complex geometry, lysine accessibility, or pathway engagement.
Guide E3 Ligase and Degradation Strategy Selection
Degradability conclusions translate directly into strategy: which E3 ligase to recruit, which degrader modality to build, and whether a PROTAC, molecular glue, or lysosome-directed approach fits the target's biology best.
Improve Candidate Prioritization and Research Efficiency
Assessment data supports PROTAC design based on bioinformatics and evidence-based portfolio decisions, replacing intuition-driven target bets with measurable degradability criteria.
Workflow
Our Target Degradability Assessment Workflow
01
Target Information Review and Assessment Planning
We collect target sequence, isoforms, subcellular localization, tissue expression, known ligands, crystal or predicted structures, and any prior degradation data, then define a tiered assessment plan matched to the target class and the client's key questions.
02
Target Structure and Ligandability Assessment
Our team builds or refines target structures through protein structure modeling, performs systematic pocket analysis, and evaluates ligand binding modes using molecular docking to judge how readily a degrader warhead can be anchored.
03
E3 Ligase Compatibility and Ternary Complex Evaluation
We profile E3 ligase expression and activity in the relevant cellular context, then combine in silico protein-protein interaction prediction with ternary complex modeling and experimental cooperativity assays to identify which E3 ligases can productively engage the target.
04
Cellular Degradation Efficiency and Kinetics Profiling
Using disease-relevant cell models, we quantify target loss after degrader treatment, measuring DC50, Dmax, degradation speed, and protein resynthesis dynamics to establish whether degradation depth is sufficient for the intended biology.
05
Degradation Mechanism and Selectivity Validation
Proteasome or lysosome inhibitor rescue experiments, E3 dependency tests, and proteome-wide selectivity profiling confirm that protein loss occurs through the intended mechanism and does not reflect broad cytotoxicity or off-target degradation.
06
Data Integration and Degradability Recommendations
All structural, biochemical, and cellular results are integrated into a structured report containing a degradability conclusion, identified barriers, recommended E3 ligases and degradation modality, and practical suggestions for the next design round.
Need Help at a Specific Assessment Stage?
From initial ligandability review to troubleshooting failed degradation, BOC Sciences can support the individual experiments your project needs.
Why Us
Why Choose BOC Sciences for Target Degradability Assessment?
Target-Specific Assessment Strategies
We do not run one fixed assay panel for every target. Each assessment plan is built around the target's protein class, localization, known biology, and available ligand information, so the data generated directly answers the client's actual question.
Integrated Computational and Experimental Capabilities
Structure modeling, docking, and interaction prediction generate hypotheses; SPR, ternary complex assays, ubiquitination assays, and cellular degradation assays test them. This closed loop lets us interpret negative results as precisely as positive ones.
Multiple Assays for Reliable Degradation Confirmation
Degradation claims require orthogonal evidence. We confirm target loss through independent readouts spanning binding, engagement, ternary complex formation, ubiquitination, protein depletion, and pathway response, protecting clients from misleading single-assay conclusions.
Flexible Support for Different TPD Development Stages
Whether you need a rapid feasibility opinion on a novel target, a systematic diagnosis of a stalled degrader series, or a full multi-module assessment program, our services scale to your project stage and connect seamlessly to downstream degrader design and evaluation.
Applications
Applications of Target Degradability Assessment in TPD Development
Early Target Feasibility and Prioritization
Before committing to degrader synthesis, research teams use our assessment to rank candidate targets by realistic degradation potential, building a solid foundation for subsequent PROTAC design services.
E3 Ligase and Degradation Strategy Selection
Assessment data on E3 expression, activity, and target compatibility directly informs the design of the ligase system, ensuring the chosen recruiter matches the biology of the disease model.
Investigation of Poor or Inconsistent Target Degradation
For stalled degrader series, our diagnostic workflow identifies whether weak degradation stems from engagement, E3 mismatch, ternary geometry, or lysine inaccessibility, guiding targeted linker design and optimization decisions.
Degrader Candidate Comparison and Lead Optimization
Analog series are compared using matched DC50, Dmax, kinetics, and selectivity datasets, giving medicinal chemists a quantitative basis for selecting lead degraders with the best degradation-to-liability balance.
Have One of These or Another TPD Application in Mind?
BOC Sciences supports the applications above and other TPD research needs. Our tailored assessments help evaluate target degradability and guide your next steps.
Case Study
Case Studies: Target Degradability Assessment for TPD
Project Background
A US-based oncology biotech was developing a CRBN-recruiting PROTAC targeting CDK for solid tumor research. The degrader bound CDK4 potently and blocked proliferation, yet endogenous degradation plateaued below 40% (Dmax). Unsure whether the ceiling came from the warhead, the E3 ligase, or the target itself, the client commissioned a systematic degradability assessment.
BOC Sciences Solutions
- Ligandability Confirmation: SPR and ITC confirmed nanomolar warhead binding to CDK4, ruling out the binding step as the bottleneck.
- Ternary Complex Diagnostics: TR-FRET assays revealed weak ternary complex formation with negative cooperativity, and Cellular BRET assays indicated limited target-E3 proximity inside cells.
- Ubiquitination Analysis: IP-western showed sparse CDK4 polyubiquitination, and molecular dynamics simulation indicated that the dominant lysine cluster was buried at the target-E3 interface.
- Geometry Exploration: We tested twelve analogs combining two E3 recruiting systems (CRBN and VHL) with three linker attachment vectors, ranking each design by cooperativity and ubiquitination intensity.
Project Outcomes
CDK4 proved fully degradable; the barrier was ternary geometry. A VHL-recruiting analog with a relocated exit vector achieved positive cooperativity, lifted Dmax above 85%, and improved DC50 by approximately eightfold, with proteomics confirming clean on-target selectivity. The client advanced this analog into its next development phase.
Project Background
A European biotech's STAT3 degrader series bound the SH2 domain potently and degraded STAT3 in engineered reporter cells, yet failed completely in the primary immune cells central to their immune-oncology program. Facing possible shutdown, the client asked whether STAT3 was fundamentally undegradable.
BOC Sciences Solutions
- E3 Landscape Profiling: RNA-seq and targeted proteomics across the client's primary immune models revealed very low CRBN expression but abundant IAP family ligases, reframing the problem as one of E3 compatibility rather than target undegradability.
- Multi-E3 Comparison: Matched degrader designs recruiting CRBN, VHL, IAP, and MDM2 were compared using bead-based luminescent proximity assays and cellular BRET-based proximity measurements.
- Endogenous Validation: The best designs were validated by Western blot DC50 and Dmax determination in primary cells, plus RT-qPCR and proteome-wide selectivity profiling to confirm on-target mechanism.
Project Outcomes
Among the four E3 strategies explored, the IAP-based PROTAC development route proved clearly superior: the IAP-recruiting design formed a cooperative ternary complex, achieved approximately 80% Dmax of endogenous STAT3 in primary immune cells, and suppressed STAT3-dependent transcriptional outputs with confirmed selectivity. A stalled project became a viable program, with a documented explanation for every previous failure.
Frequently Asked Questions (FAQ)
How can target degradability be assessed before selecting degraders?
Target degradability assessment requires more than identifying a ligand-binding pocket. Researchers need to examine protein structure, ligandability, subcellular localization, and compatibility with cellular degradation machinery. Initial studies may include structural analysis and ligand-binding assays to identify accessible binding sites and potential E3 ligase recruitment opportunities. When suitable ligands or preliminary degraders are available, cellular target engagement, ternary complex formation, ubiquitination, and protein degradation assays can provide additional experimental evidence. For targets without established degraders, the assessment focuses on identifying feasible degradation strategies and potential barriers rather than claiming confirmed degradability. Integrating these findings helps researchers prioritize targets, select appropriate experimental approaches, and guide subsequent degrader development.
Why does strong target binding not ensure degradation?
Strong ligand binding is only one requirement for successful targeted protein degradation. For PROTACs, the target protein and E3 ligase must also form a productive ternary complex with a suitable spatial orientation for ubiquitination. Even when a ternary complex forms, degradation may remain limited if accessible ubiquitination sites are poorly positioned or the complex does not support efficient ubiquitin transfer. Cellular permeability, E3 ligase expression, subcellular localization, and protein turnover can further influence degradation efficiency. Binding affinity measurements, ternary complex assays, ubiquitination studies, and cellular degradation kinetics help identify these limitations. The results can guide linker modifications, E3 ligand selection, and other structural optimization strategies.
How is E3 ligase compatibility assessed for nuclear proteins?
E3 ligase compatibility for nuclear targets depends on more than binding affinity. The selected E3 ligase must be expressed, functionally active, and appropriately localized to interact with the nuclear target in relevant cellular models. Assessment may begin with E3 expression profiling, protein localization analysis, and evaluation of available recruitment ligands. Ternary complex assays can then compare complex formation and cooperativity across different recruitment strategies. Ubiquitination and cellular degradation experiments provide functional evidence of productive recruitment. When appropriate, E3 ligase knockdown or knockout studies can further confirm degradation dependence. Integrating these results helps identify suitable E3 recruitment strategies and supports the design of degraders for challenging nuclear proteins.
Which assays distinguish selective degradation from indirect protein loss?
Confirming selective target degradation requires multiple complementary experiments rather than a single protein abundance measurement. Western blotting or other quantitative protein assays can establish concentration-dependent and time-dependent changes in target protein levels. Measuring target mRNA helps distinguish protein depletion from changes in gene expression, although it cannot establish the degradation mechanism alone. Proteasome inhibition, E3 ligase perturbation, and competitive binding controls can provide evidence for ubiquitin-proteasome-dependent degradation. Other degradation approaches require pathway-specific validation. Quantitative proteomics can identify additional proteins whose abundance changes after treatment and help investigate potential off-target degradation. Combining orthogonal assays with appropriate controls provides a more reliable interpretation of degradation mechanism and selectivity.
What information is needed to start a degradability assessment?
To initiate a target degradability assessment, clients are encouraged to provide the target protein name, available structural information, research objectives, and relevant cellular models. Existing ligand information, PROTAC candidates, or preliminary degradation data can also help define the assessment strategy. BOC Sciences tailors experimental plans to the available information and project stage. For targets without established degraders, we can begin with structural analysis, ligand-binding feasibility, and E3 ligase compatibility assessment. For projects with existing compounds, we can investigate ternary complex formation, ubiquitination, degradation kinetics, and underlying mechanisms. Clients do not need a complete experimental dataset before starting. Our scientists help identify the most relevant assays based on each project's specific requirements.
Testimonials
Client Testimonials on Target Degradability Assessment
Uncovering Hidden Degradation Barriers
"Our degrader looked perfect on paper but refused to degrade the target. BOC Sciences walked us through ternary complex assays and ubiquitination mapping, and the real bottleneck turned out to be something we had never considered. That diagnosis saved our series."
— Dr. Murphy, Head of Protein Degradation at a German Biotechnology Company
Confidence in Target Feasibility Decisions
"We needed to decide whether to commit two years of chemistry to a novel scaffold target. Their structured assessment gave us evidence instead of opinions, and the go decision we made is still paying off in our pipeline."
— Dr. Wood, Program Lead at a US-Based Pharmaceutical Research Organization
Finding the Right E3 Ligase Match
"After months of failed CRBN degraders, we had almost written the target off. The E3 expression profiling and multi-ligase comparison they performed identified a much better recruiter for our cell models, and degradation finally worked."
— Ms. Gray, Project Manager at a French Oncology-Focused Research Institute
Turning Assay Results into Actionable Strategies
"What impressed us most was the final report. It did not just list data; it explained what limited our degradation, which design variables to change, and why. Our chemistry team started the next round the same week."
— Dr. Ortiz, Director of Medicinal Chemistry at a UK-Based Drug Discovery Company
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
